141 related articles for article (PubMed ID: 37819776)
1. Comparative cost-effectiveness of contemporary treatment strategies for stage IIA seminoma.
Joyce DD; Sharma V; Wymer KM; Moriarty JP; Borah BJ; Walia A; Costello BA; Pagliaro LC; Daneshmand S; Leibovich BC; Boorjian SA
J Natl Cancer Inst; 2024 Mar; 116(3):468-475. PubMed ID: 37819776
[TBL] [Abstract][Full Text] [Related]
2. Primary Retroperitoneal Lymph Node Dissection for Clinical Stage II A/B Seminomas: A Systematic Review and Meta-Analysis.
Melão BVLA; de Amorim LGCR; Sanches MR; Gomes GV; Gewehr DM; Moreira LHO; da Silva TP; Lobo MM; Bechara GR
Int Braz J Urol; 2024; 50(4):415-432. PubMed ID: 38701185
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST).
Hiester A; Che Y; Lusch A; Kuß O; Niegisch G; Lorch A; Arsov C; Albers P
Eur Urol; 2023 Jul; 84(1):25-31. PubMed ID: 36372627
[TBL] [Abstract][Full Text] [Related]
4. Retroperitoneal lymph node dissection for testicular seminomas: population-based practice and survival outcomes.
Patel HD; Joice GA; Schwen ZR; Semerjian A; Alam R; Srivastava A; Allaf ME; Pierorazio PM
World J Urol; 2018 Jan; 36(1):73-78. PubMed ID: 29026972
[TBL] [Abstract][Full Text] [Related]
5. Retroperitoneal Lymph Node Dissection as First-Line Treatment of Node-Positive Seminoma.
Hu B; Shah S; Shojaei S; Daneshmand S
Clin Genitourin Cancer; 2015 Aug; 13(4):e265-e269. PubMed ID: 25682512
[TBL] [Abstract][Full Text] [Related]
6. Post-chemotherapy laparoscopic retroperitoneal lymph node dissection is feasible for stage IIA/B non-seminoma germ cell tumors.
Nakamura T; Kawauchi A; Oishi M; Ueda T; Shiraishi T; Nakanishi H; Kamoi K; Naya Y; Hongo F; Okihara K; Miki T
Int J Clin Oncol; 2016 Aug; 21(4):791-795. PubMed ID: 26701172
[TBL] [Abstract][Full Text] [Related]
7. Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy.
Daneshmand S; Cary C; Masterson T; Einhorn L; Adra N; Boorjian SA; Kollmannsberger C; Schuckman A; So A; Black P; Bagrodia A; Skinner E; Alemozaffar M; Brand T; Eggener S; Pierorazio P; Stratton K; Nappi L; Nichols C; Luo C; Li M; Hu B
J Clin Oncol; 2023 Jun; 41(16):3009-3018. PubMed ID: 36913642
[TBL] [Abstract][Full Text] [Related]
8. Retroperitoneal lymph-node dissection (RPLND) as upfront management in stage II germ-cell tumours: Evaluation of safety and efficacy.
Nicolai N; Nazzani S; Tesone A; Macchi A; Piva L; Salvioni R; Stagni S; Torelli T; Agostini E; Celso F; Giannatempo P; Procopio G; Avuzzi B; Lanocita R; Cattaneo L; Catanzaro M; Biasoni D
Tumori; 2023 Aug; 109(4):379-386. PubMed ID: 35915559
[TBL] [Abstract][Full Text] [Related]
9. Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014.
Tabakin AL; Shinder BM; Kim S; Rivera-Nunez Z; Polotti CF; Modi PK; Sterling JA; Farber NJ; Radadia KD; Parikh RR; Kim IY; Saraiya B; Mayer TM; Singer EA; Jang TL
Clin Genitourin Cancer; 2020 Apr; 18(2):e194-e201. PubMed ID: 31818649
[TBL] [Abstract][Full Text] [Related]
10. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
11. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
12. Primary laparoscopic RPLND for pure seminona metastasis: feasibility of supine and lateral approaches.
Santos VE; Fornazieri L; Brazão ES; Pinto PR; da Costa WH; Zequi SC
Int Braz J Urol; 2023; 49(2):269-270. PubMed ID: 36037258
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of miR-371a-3p to predict viable germ cell tumor in patients with pure seminoma receiving retroperitoneal lymph node dissection.
Konneh B; Lafin JT; Howard J; Gerald T; Amini A; Savelyeva A; Woldu SL; Lewis CM; Jia L; Margulis V; Coleman N; Scarpini C; Frazier AL; Murray MJ; Amatruda JF; Bagrodia A
Andrology; 2023 May; 11(4):634-640. PubMed ID: 36254623
[TBL] [Abstract][Full Text] [Related]
14. Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for seminoma: Limitations of surgical intervention after first-line chemotherapy.
Tachibana I; Alabd A; Whaley RD; McFadden J; Piroozi A; Hassoun R; Kern SQ; King J; Adra N; Rice KR; Foster RS; Einhorn LH; Cary C; Masterson TA
Urol Oncol; 2023 Sep; 41(9):394.e1-394.e6. PubMed ID: 37543446
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.
Lam SW; Wai M; Lau JE; McNamara M; Earl M; Udeh B
Pharmacotherapy; 2017 Jan; 37(1):94-103. PubMed ID: 27870079
[TBL] [Abstract][Full Text] [Related]
16. Contemporary management of early stage testicular seminoma.
Aydin AM; Zemp L; Cheriyan SK; Sexton WJ; Johnstone PAS
Transl Androl Urol; 2020 Jan; 9(Suppl 1):S36-S44. PubMed ID: 32055484
[TBL] [Abstract][Full Text] [Related]
17. Current controversies on the role of retroperitoneal lymphadenectomy for testicular cancer.
Mano R; Di Natale R; Sheinfeld J
Urol Oncol; 2019 Mar; 37(3):209-218. PubMed ID: 30446455
[TBL] [Abstract][Full Text] [Related]
18. Retroperitoneal Lymph Node Dissection as Primary Treatment for Metastatic Seminoma.
Hu B; Daneshmand S
Adv Urol; 2018; 2018():7978958. PubMed ID: 29487620
[TBL] [Abstract][Full Text] [Related]
19. The role of primary retroperitoneal lymph node dissection in the treatment of stage II seminoma.
Sigg S; Fankhauser CD
Curr Opin Urol; 2023 Jul; 33(4):245-251. PubMed ID: 37144886
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Choe JH; Abdel-Azim H; Padula WV; Abou-El-Enein M
JAMA Netw Open; 2022 Dec; 5(12):e2245956. PubMed ID: 36520440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
